Conclusions
lung tumors
LUNG TUMORS
This proof-of-principle, phase 1 nonrandomized controlled trial demonstrates that the CEACAM5-targeted NIR tracer SGM-101 can detect CEACAM5 glycoprotein–positive lung tumors. Ideal patients are those with lesions larger than 1.0 cm who are CEACAM5 positive or patients with positive serum CEA levels. Additional, larger-scale trials are needed to validate the study findings, but the current results demonstrate that CEACAM5 surface glycoprotein targeting is a feasible target with clinical utility.